Challenges and opportunities with modelling and simulation in drug discovery and drug development

The benefits of modelling and simulation at the pre-clinical stage of drug development can be realized through formal and realistic integration of data on physicochemical properties, pharmacokinetics, pharmacodynamics, formulation and safety. Such data integration and the powerful combination of physiologically based pharmacokinetic (PBPK) with pharmacokinetic–pharmacodynamic relationship (PK/PD) models provides the basis for quantitative outputs allowing comparisons across compounds and resulting in improved decision-making during the selection process. Such PBPK/PD evaluations provide crucial information on the potency and safety of drug candidates in vivo and the bridging of the PK/PD concept established during the pre-clinical phase to clinical studies. Modelling and simulation is required to address a number of key questions at the various stages of the drug-discovery and -development process. Such questions include the following. (1) What is the expected human PK profile for potential clinical candidate(s)? (2) Is this profile and its associated PD adequate for the given indication? (3) What is the optimal dosing schedule with respect to safety and efficacy? (4) Is a food effect expected? (5) How can formulation be improved and what is the potential benefit? (6) What is the expected variability and uncertainty in the predictions?

[1]  K Rowland-Yeo,et al.  Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  M. Andersen.  Physiologically based pharmacokinetic (PB-PK) models in the study of the disposition and biological effects of xenobiotics and drugs. , 1995, Toxicology Letters.

[3]  Ivan Nestorov,et al.  Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.

[4]  G. Tucker,et al.  Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  Y. Sugiyama,et al.  Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. , 2003, Drug metabolism and pharmacokinetics.

[6]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[7]  Malcolm Rowland,et al.  Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[8]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[9]  Meindert Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. , 2007, Annual review of pharmacology and toxicology.

[10]  Seth Michelson,et al.  The impact of systems biology and biosimulation on drug discovery and development. , 2006, Molecular bioSystems.

[11]  M E Andersen,et al.  Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. , 1995, Toxicology letters.

[12]  Alex Bangs,et al.  Predictive biosimulation and virtual patients in pharmaceutical R and D. , 2005, Studies in health technology and informatics.

[13]  S.S. Demir,et al.  BME company profiles entelos: predictive model systems for disease , 2005, IEEE Engineering in Medicine and Biology Magazine.

[14]  M Rowland,et al.  Physiologic pharmacokinetic models and interanimal species scaling. , 1985, Pharmacology & therapeutics.

[15]  A. Rostami-Hodjegan,et al.  'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. , 2004, Drug discovery today. Technologies.

[16]  Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics. , 1994, Toxicology in vitro : an international journal published in association with BIBRA.

[17]  Malcolm Rowland,et al.  Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  J B Houston,et al.  Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.

[19]  David E. Leahy,et al.  Drug discovery information integration: virtual humans for pharmacokinetics , 2004 .

[20]  H J Clewell,et al.  Applying simulation modeling to problems in toxicology and risk assessment--a short perspective. , 1995, Toxicology and applied pharmacology.

[21]  A. Kansal,et al.  Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design. , 2005, Systems biology.

[22]  Malcolm Rowland,et al.  Fuzzy Simulation of Pharmacokinetic Models: Case Study of Whole Body Physiologically Based Model of Diazepam , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[23]  Walter Schmitt,et al.  Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[24]  G. E. Searle,et al.  APPLICATION OF A GENERIC PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO THE ESTIMATION OF XENOBIOTIC LEVELS IN RAT PLASMA , 2006, Drug Metabolism and Disposition.

[25]  M. Vaughn,et al.  Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. , 2001, The Journal of pharmacology and experimental therapeutics.

[26]  Thierry Lavé,et al.  An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. , 2005, Journal of pharmaceutical sciences.

[27]  Thierry Lavé,et al.  Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. , 2005, Basic & clinical pharmacology & toxicology.

[28]  G. Searle,et al.  APPLICATION OF A GENERIC PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO THE ESTIMATION OF XENOBIOTIC LEVELS IN HUMAN PLASMA , 2006, Drug Metabolism and Disposition.

[29]  Y. Sugiyama,et al.  Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.

[30]  I. Nestorov,et al.  Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. , 2001, Toxicology letters.

[31]  G. Tucker,et al.  Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  J B Houston,et al.  Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. , 2001, British journal of clinical pharmacology.

[33]  Thierry Lavé,et al.  Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling , 2006, Clinical pharmacokinetics.

[34]  Seth Michelson.  Assessing the Impact of Predictive Biosimulation on Drug Discovery and Development , 2003, J. Bioinform. Comput. Biol..

[35]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[36]  J. Dressman,et al.  Comparison of Canine and Human Gastrointestinal Physiology , 1986, Pharmaceutical Research.

[37]  Ivan Nestorov,et al.  Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.

[38]  Andreas Reichel,et al.  Development and Application of Physiologically Based Pharmacokinetic‐Modeling Tools to Support Drug Discovery , 2005, Chemistry & biodiversity.

[39]  Stephanie Läer,et al.  Population pharmacokinetic studies in pediatrics: Issues in design and analysis , 2005, The AAPS Journal.

[40]  T. Lavé,et al.  A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.

[41]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[42]  Melvin E. Andersen,et al.  Physiologically-Based Pharmacokinetic Modeling* , 1994 .

[43]  Ivelina Gueorguieva,et al.  Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[44]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). , 2004, AAPS pharmSci.